These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1635 related articles for article (PubMed ID: 32415696)
1. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696 [TBL] [Abstract][Full Text] [Related]
2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
3. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331 [TBL] [Abstract][Full Text] [Related]
4. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S; Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267 [TBL] [Abstract][Full Text] [Related]
5. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Wijetunga AR; Chua TC; Nahm CB; Pavlakis N; Clarke S; Chan DL; Diakos C; Maloney S; Ashrafi-Zadeh A; Kneebone A; Hruby G; Jamieson NB; Gill A; Mittal A; Samra JS Eur J Surg Oncol; 2021 Oct; 47(10):2543-2550. PubMed ID: 33952409 [TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153 [TBL] [Abstract][Full Text] [Related]
8. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis. Dong LP; Liu YM; Lu WJ; Tang KZ Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6316-6327. PubMed ID: 36111933 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667 [TBL] [Abstract][Full Text] [Related]
12. Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population. Walpole I; Lee B; Shapiro J; Thomson B; Lipton L; Ananda S; Usatoff V; Mclachlan SA; Knowles B; Fox A; Wong R; Cooray P; Burge M; Clarke K; Pattison S; Nikfarjam M; Tebbutt N; Harris M; Nagrial A; Zielinski R; Chee CE; Gibbs P Asia Pac J Clin Oncol; 2023 Feb; 19(1):214-225. PubMed ID: 35831999 [TBL] [Abstract][Full Text] [Related]
13. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Eshmuminov D; Aminjonov B; Palm RF; Malleo G; Schmocker RK; Abdallah R; Yoo C; Shaib WL; Schneider MA; Rangelova E; Choi YJ; Kim H; Rose JB; Patel S; Wilson GC; Maloney S; Timmermann L; Sahora K; Rössler F; Lopez-Lopez V; Boyer E; Maggino L; Malinka T; Park JY; Katz MHG; Prakash L; Ahmad SA; Helton S; Jang JY; Hoffe SE; Salvia R; Taieb J; He J; Clavien PA; Held U; Lehmann K Ann Surg Oncol; 2023 Jul; 30(7):4417-4428. PubMed ID: 37020094 [TBL] [Abstract][Full Text] [Related]
14. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
15. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Tran NH; Sahai V; Griffith KA; Nathan H; Kaza R; Cuneo KC; Shi J; Kim E; Sonnenday CJ; Cho CS; Lawrence TS; Zalupski MM Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):124-133. PubMed ID: 31494181 [TBL] [Abstract][Full Text] [Related]
17. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407. Tezuka S; Ozaka M; Furuse J; Yokoyama M; Uemura K; Sano Y; Nakachi K; Imaoka H; Unno M; Shirakawa H; Shimizu S; Kato N; Kojima Y; Sano K; Kobayashi S; Terashima T; Morizane C; Ikeda M; Ueno M Pancreatology; 2024 Sep; 24(6):909-916. PubMed ID: 39060124 [TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]